Inhibition by fluoxetine of cytochrome P450 2D6 activity

@article{Otton1993InhibitionBF,
  title={Inhibition by fluoxetine of cytochrome P450 2D6 activity},
  author={S. Victoria Otton and D Wu and Russell T. Joffe and Siu Wah Cheung and Edward Sellers},
  journal={Clinical Pharmacology \& Therapeutics},
  year={1993},
  volume={53}
}
Potent inhibition of cytochrome P450 2D6 (CYP2D6) in human liver microsomes by fluoxetine and its major metabolite norfluoxetine was confirmed (apparent inhibition constant values, 0.2 μmol/L). Several other serotonergic agents were also found to be competitive inhibitors of this genetically polymorphic enzyme. The O‐demethylation ratio of dextromethorphan that expressed CYP2D6 activity in 19 patients receiving fluoxetine fell in the region of the antimode separating the O‐demethylation ratio… Expand
Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.
TLDR
It is concluded that pharmacokinetic interaction between fluvoxamine and theophylline is due to potent inhibition of CYP1A2, which are equally important isoforms for the 8-hydroxylation of theophyLLine. Expand
Human cytochromes mediating N-demethylation of fluoxetine in vitro
TLDR
In human liver microsomes, formation of norfluoxetine from R,S-fluxetine was consistent with Michaelis-Menten kinetics, with evidence of substrate inhibition at high substrate concentrations in a number of cases, and Cytochrome P450-2C9 appears to be the principal human cytochrome mediating fluoxettine N-demethylation. Expand
The Inhibitory Effect of Amoxapine on Cytochrome P450 Enzyme Activity in Human Liver Microsomes
TLDR
It is concluded that amoxapine would not cause the severe drug-drug interaction mediated by CYP enzymes, and inhibition of CYP2D6 and CYP3A4 enzyme activity by am oxapine is based on a competitive mechanism. Expand
Inhibition of Human Cytochrome P450‐3A Isoforms by Fluoxetine and Norfluoxetine: In Vitro and In Vivo Studies
TLDR
Both in vitro and in vivo data clearly demonstrate that fluoxetine, norfluoxETine, and paroxetines are highly potent inhibitors of human Cytochrome P450-2D6,25 producing very large impairment in clearance of drugs metabolized by this cytochrome. Expand
Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
In vitro preparations of human liver microsomes were used to study the inhibiting effects of two selective serotonin reuptake inhibitor (SSRI) antidepressants, paroxetine and fluvoxamine, onExpand
Antidepressant Drug Interactions and the Cytochrome P450 System
TLDR
The extent of the in vivo interaction between the SSRIs and tricyclic antidepressants mirrors to a large extent their in vitro inhibitory potencies against CYP2D6 and other isoenzyme systems, especially if one takes into account pharmacokinetic factors. Expand
Venlafaxine oxidation in vitro is catalysed by CYP2D6.
TLDR
In vitro findings predict phenotypic differences in the kinetics of venlafaxine in vivo, although the clinical importance of this is unclear as O-demethylvenlafxine is pharmacologically similar to the parent drug. Expand
Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes.
TLDR
In vitro data suggest that an in vivo interaction between propafenone and the SSRIs, fluoxetine and parxetine, can be expected, which can lead to clinically relevant beta-blockade and an increased risk of side effects in the central nervous system. Expand
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.
TLDR
Since its inhibition is very potent and has a broad "window of selectivity," omeprazole seems to be a useful, selective inhibitor of CYP2C19, and lansoprazole may be the more important in vitro inhibitor of CyP2D6. Expand
Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity
The majority of marketed small-molecule drugs undergo metabolism by hepatic Cytochrome P450 (CYP) enzymes (Rendic 2002). Since these enzymes metabolize a structurally diverse number of drugs,Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
TLDR
It is suggested that compounds with SSRI activity are likely to interact with human CYP2D6 in vivo with the potential of causing drug interactions. Expand
Effect of fluoxetine on plasma desipramine and 2-hydroxydesipramine
TLDR
A case study in which fluoxetine, when added to DMI, indeed alters the drug-metabolite ratio of the TCA, and this combination proved to be beneficial to the patient. Expand
Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype
TLDR
The formation of mesoridazine from thioridazine and the 4‐hydroxylation of debrisoquin seem to be catalyzed by the same enzyme, whereas the formation of thIORidazine ring‐sulphoxide is probably formed mainly by another enzyme. Expand
The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
TLDR
The therapeutic implications for each of the classes of drugs affected by this genetic polymorphism in drug metabolism are discussed and it is emphasized that it is difficult to attain therapeutic plasma concentrations for some drugs in high activity extensive metabolizers. Expand
Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man.
TLDR
The inhibitory effects of midazolam and dehydroepiandrosterone support the contention that the N-demethylase is a human foetal form of the cytochrome P450 IIIA family. Expand
Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.
TLDR
In 20 depressed patients treated with nortriptyline (NT) there was a significant relationship between the plasma concentration of NT and the debrisoquine metabolic ratio (rs = 0.77; P less than 0.01), in agreement with the hypothesis that the hydroxylations ofNT and debrisquine are mediated by similar enzymatic mechanisms. Expand
Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
TLDR
The data suggest that the poor metabolizer phenotype in livers expressing CYP2D6(C) is not due to a catalytically defective enzyme but perhaps due to decreased levels of the P450 protein in microsomal membranes. Expand
Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
TLDR
This study demonstrates the efficiency of the PCR-test for phenotype prediction; 96.4% of individuals were correctly predicted, i.e., 100% of the extensive metabolizers (EMs) and 86.0%" of the poor metabolizer phenotype (PMs). Expand
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.
TLDR
PM of debrisoquine (7% of Caucasian populations) might, therefore, on common doses of haloperidol, achieve high plasma concentrations and thereby have an increased risk of side effects and at the other extreme, very rapid metabolizers may need increased doses of Haloperidols. Expand
The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam
TLDR
The clinical implications of this pharmacokinetic drug‐drug interaction are minor because psychomotor responses were unaffected and offsetting changes in the kinetics of diazepam and its metabolite occurred, and Dosage modification of either fluoxetine or diazepAM is unlikely to be necessary. Expand
...
1
2
3
4
5
...